Biohaven Ltd. (BHVN) vs Urogen Pharma (URGN)

Biohaven Ltd. and Urogen Pharma are both Biotechnology companies. Biohaven Ltd. and Urogen Pharma are of similar size ($2.0B and $2.0B). Biohaven Ltd. grew revenue faster over the last twelve months: 425.2% against 100.3%. Biohaven Ltd. has the higher net margin (0.00% vs −51.7%) and the lower return on invested capital (−9,245.4% vs 0.00%). Across the 16 metrics below, Biohaven Ltd. leads on 8 and Urogen Pharma on 8.

Valuation

Metric BHVN URGN Biotechnology median
P/E n/m n/m 7.88
P/S 1.97 11.04 11.47
P/B 160.10 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.96 11.47 10.73
Earnings yield (35.72%) (4.79%) (28.84%)
Free cash flow yield (27.17%) (7.64%) (23.03%)

Profitability

Metric BHVN URGN Biotechnology median
Gross margin 0.00% 90.85% 65.16%
Operating margin 0.00% (35.32%) 0.00%
Net margin 0.00% (51.73%) 0.00%
Free cash flow margin 0.00% (84.32%) 0.00%
Return on equity (799.46%) 86.49% (57.72%)
Return on assets (127.41%) (42.33%) (49.22%)
Return on invested capital (9,245.36%) 0.00% 0.00%

Growth

Metric BHVN URGN Biotechnology median
Revenue growth (TTM) 425.20% 100.27% 5.64%
EPS growth (last fiscal year) 26.08% (7.77%) —
Revenue growth, 5-year CAGR — 56.22% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BHVN URGN Biotechnology median
Debt to equity 21.23 (1.45) 0.00
Current ratio 4.73 3.80 4.73
Net debt to EBITDA 0.11 0.00 0.96

Dividend

Metric BHVN URGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BHVN URGN Biotechnology median
Market cap 1.99b 2.02b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack